CERUS CORP

CERS Nasdaq CIK: 0001020214

Company Information

Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Accelerated filer
State of Incorporation DE
Business Address 1220 CONCORD AVENUE, CONCORD, CA, 94520
Mailing Address 1220 CONCORD AVENUE, CONCORD, CA, 94520
Phone 9252886000
Fiscal Year End 1231
EIN 680262011

Financial Overview

FY2025

$156.89M
Total Liabilities
$64.22M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) March 24, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
8-K Current report of material events March 16, 2026 View on SEC
4/A Insider transaction amendment March 10, 2026 View on SEC
4 Insider stock transaction report March 9, 2026 View on SEC

Annual Reports

10-K March 2, 2026
  • FDA approval of INTERCEPT red blood cell system unlocks a substantial new U.S. market opportunity.
  • Achieved 12% year-over-year revenue growth to $165 million, driven by global adoption.
View Analysis

Material Events

8-K Leadership Change March 16, 2026
High Impact
  • Planned succession: Vivek Jayaraman promoted to President and CEO, with outgoing CEO William Greenman becoming Executive Chairman.
  • New CEO brings extensive experience (COO since 2020, CCO since 2016) to accelerate growth and market penetration.
View Analysis

Insider Trading

STRONG SELL 5 insiders 15 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 3841)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.